Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen

Infection and Immunity

Volumn 73, Issue 9, 2005, Pages 5928-5935

  Tetteh, Kevin K A ^a   Cavanagh, David R ^b   Corran, Patrick ^a   Musonda, Rosemary ^c   McBride, Jana S ^b   Conway, David J ^a,d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c TROPICAL DISEASES RESEARCH CENTRE   (Zambia)

^d MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1;

ADULT; AGED; ALLELE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; DNA POLYMORPHISM; DRUG DESIGN; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNIZATION; MAJOR CLINICAL STUDY; MALARIA; MEROZOITE; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY SPECIFICITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNOASSAY; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MICE; MIDDLE AGED; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; REPETITIVE SEQUENCES, AMINO ACID;

EID: 23944438482     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.9.5928-5935.2005     Document Type: Article

References (35)

1. Al-Yaman, F., B. Genton, R. Anders, J. Taraika, M. Ginny, S. Mellor, and M. P. Alpers. 1995. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. Parasite Immunol. 17:493-501.
2. Bush, R. M., C. A. Bender, K. Subbarao, N. J. Cox, and W. M. Fitch. 1999. Predicting the evolution of human influenza A. Science 286:1921-1925.
3. Cavanagh, D. R., D. Dodoo, L. Hviid, J. A. L. Kurthals, B. D. Akanmori, S. Policy, D. J. Conway, K. Koram, and J. S. McBride. 2004. Antibodies to N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect. Immun. 72:6492-6502.
4. Cavanagh, D. R., I. M. Elhassan, C. Roper, V. J. Robinson, H. Giha, A. A. Holder, L. Hviid, T. G. Theander, D. E. Arnot, and J. S. McBride. 1998. A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J. Immunol. 161:347-359.
5. Cavanagh, D. R., and J. S. McBride. 1997. Antigenicity of recombinant proteins derived from Plasmodium falciparum merozoite surface protein 1. Mol. Biochem. Parasitol. 85:197-211.
6. Conway, D. J. 1997. Natural selection on polymorphic malaria antigens and the search for a vaccine. Parasitol. Today 13:26-29.
7. Conway, D. J., D. R. Cavanagh, K. Tanabe, C. Roper, Z. S. Mikes, N. Sakihama, K. A. Bojang, A. M. J. Oduola, P. G. Kremsner, D. E. Arnot, B. M. Greenwod, and J. S. McBride. 2000. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat. Med. 6:689-692.
8. Conway, D. J., C. Roper, A. M. J. Oduola, D. E. Arnot, P. G. Kremsner, M. P. Grobusch, C. F. Curtis, and B. M. Greenwood. 1999. High recombination rate in natural populations of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 96:4506-4511.
9. Cutts, F. T., S. M. Zaman, G. Enwere, S. Jaffar, O. S. Levine, J. B. Okoko, C. Oluwalana, A. Vaughan, S. K. Obaro, A. Leach, K. P. McAdam, E. Biney, M. Saaka, U. Onwuchekwa, F. Yallop, N. F. Pierce, B. M. Greenwood, et al. 2005. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365:1139-1146.
10. Ekala, M.-T., H. Jouin, F. Lekoulou, S. Issifou, O. Mercereau-Puyalon, and F. Ntoumi. 2002. Plasmodium falciparum merozoite surface protein 1 (MSP1): genotyping and humoral responses to allele-specific variants. Acta Trop. 81:33-46.
11. Ferreira, M. U., W. L. Ribeiro, A. P. Tonon, F. Kawamoto, and S. M. Rich. 2003. Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. Gene 304:65-75.
12. Frank, R. 1997. Multiple peptide synthesis with SPOT technique, p. 763-795. In I. Lefkovits (ed.), Immunology methods manual, vol. 2. Academic Press, Ltd., London, United Kingdom.
13. Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B. Haynes, B. H. Hahn, T. Bhattacharya, and B. Korber. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296:2354-2360.
14. Genton, B., I. Betuela, I. Felger, F. Al-Yaman, R. F. Anders, A. Saul, L. Rare, M. Baisor, et al. 2002. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185:820-827.
15. Hodder, A. N., P. E. Crewther, and R. F. Anders. 2001. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 69:3286-3294.
16. Hu, M. C., M. A. Walls, S. D. Stroop, M. A. Reddish, B. Beall, and J. B. Dale. 2002. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect. Immun. 70:2171-2177.
17. Jones, T. R., R. A. Gramzinsk, J. C. Aguiar, B. K. Sim, D. L. Narum, S. R. Fuhrmann, S. Kumar, N. Obaldia, and S. L. Hoffman. 2002. Absence of antigenic competition in Aotus monkeys immunized with Plasmodium falciparum DNA vaccines delivered as a mixture. Vaccine 20:1675-1680.
18. Jouin, H., C. Rogier, J. F. Trape, and O. Mercereau-Puijalon. 2001. Fixed, epitope-specific, cytophilic antibody response to the polymorphic block 2 domain of the Plasmodium falciparum merozoite surface antigen MSP-1 in humans living in a malaria-endemic area. Eur. J. Immunol. 31:539-550.
19. Kennedy, M. C., J. Wang, Y. Zhang, A. P. Miles, F. Chitsaz, A. Saul, C. A. Long, L. H. Miller, and A. W. Stowers. 2002. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. 70:6948-6960.
20. Klugman, K. P., S. A. Madhi, R. E. Huebner, R. Kohberger, N. Mbelle, N. Pierce, and V. T. Group. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349:1341-1348.
21. Kocken, C. H. M., C. Withers-Martinez, M. A. Dubbeld, A. van der Wel, F. Hackett, M. J. Blackman, and A. W. Thomas. 2002. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect. Immun. 70:4471-4476.
22. Kreitman, M. 2000. Methods to detect selection in populations with application to the human. Annu. Rev. Genomics Hum. Genet. 1:539-559.
23. Lipsitch, M. 2002. Vaccination and serotype replacement, p. 362-374. In U. Dieckmann, J. A. J. Metz, M. W. Sabelis, and K. Sigmund (ed.), Adaptive dynamics of infectious diseases: in pursuit of virulence management. Cambridge University Press, Cambridge, United Kingdom.
24. Locher, C. P., L. Q. Tam, S. P. Chang, J. S. McBride, and W. A. Siddiqui. 1996. Plasmodium falcipamm: gp195 tripeptide repeat-specific monoclonal antibody inhibits parasite growth in vitro. Exp. Parasitol. 84:74-83.
25. Martin, S. L., R. Borrow, P. van der Ley, M. Dawson, A. J. Fox, and K. A. V. Cartwright. 2000. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 18:2476-2481.
26. Mawili-Mboumba, D. P., S. Borrmann, D. R. Cavanagh, J. S. McBride, P. B. Matsiegui, M. A. Missinou, P. G. Kremsner, and F. Ntoumi. 2003. Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria. J. Infect. Dis. 187:1137-1141.
27. Metzger, W. G., D. M. N. Okenu, D. R. Cavanagh, J. V. Robinson, K. A. Bojang, H. A. Weiss, J. S. McBride, B. M. Greenwood, and D. J. Conway. 2003. Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol. 25:307-312.
28. Miller, L. H., T. Roberts, M. Shahabuddin, and T. F. McCutchan. 1993. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol. Biochem. Parasitol. 59:1-14.
29. Okenu, D. M. N., E. M. Riley, Q. D. Bickle, P. U. Agomo, A. Barbosa, J. R. Daugherty, D. E. Lanar, and D. J. Conway. 2000. Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infect. Immun. 68:5559-5566.
30. Polley, S. D., W. Chokejindachai, and D. J. Conway. 2003. Allele frequency based analyses robustly identify sites under balancing selection in a malaria vaccine candidate antigen. Genetics 165:555-561.
31. Polley, S. D., and D. J. Conway. 2001. Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 (ama1) gene. Genetics 158:1505-1512.
32. Polley, S. D., K. K. A. Tetteh, D. R. Cavanagh, R. J. Pearce, J. M. Lloyd, K. A. Bojang, D. M. N. Okenu, B. M. Greenwood, J. S. McBride, and D. J. Conway. 2003. Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria. Infect. Immun. 71:1833-1842.
33. Richie, T. L., and A. Saul. 2002. Progress and challenges for malaria vaccines. Nature 415:694-701.
34. Taylor, R. R., S. J. Allen, B. M. Greenwood, and E. M. Riley. 1998. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am. J. Trop. Med. Hyg. 58:406-413.
35. Tine, J. A., D. E. Lanar, D. M. Smith, et al. 1996. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 64:3833-3844.